Human equilibrative nucleoside transporter 1 (hENT1): Do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?

摘要: Although systemic chemotherapy significantly improves the overall survival of pancreatic cancer patients, prognosis remains extremely poor. The development a drug resistance, either de novo or induced limits effectiveness chemotherapy. SLC29A1 gene encodes human equilibrative nucleoside transporter 1 (hENT1) protein that is mediating transport nucleotides, both purines and pyrimidines, into tumor cells. aim this mini-review to summarize current information concerning prognostic predictive role expression in cancer. Increased in vitro has been described as potential critical factor determining sensitivity cells gemcitabine 5-fluorouracil, principal cytotoxic agents used treatment reports on relationship between patients with are currently rather conflicting. However, majority studies resected have suggested high SLC29A1expression may be improved treated gemcitabine. not shown represent biomarker for by 5-fluorouracil. In conclusion, demonstrated selected subset patients.